Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

Ocugen (OCGN) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to loss of$0.06 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biotech knee implant developer would post a loss of $0.06 per share when it actually produced a loss of$0.04, delivering a surprise of 33.33%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Ocugen, which belongs to the ...